For the quarter ending 2025-09-30, BRTX had -$952,807 decrease in cash & cash equivalents over the period. -$2,901,137 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -3,038,277 | -7,996,062 |
| Depreciation and amortization | 52,620 | 104,529 |
| Dividend and interest income | 59,336 | 176,542 |
| Stock-based compensation | 399,932 | 2,477,834 |
| Change in fair value of warrant liabilities | 612,064 | -59,528 |
| Accounts receivable | -1,600 | -173,400 |
| Prepaid expenses and other current assets | 2,366 | -21,359 |
| Lease liability | - | 0 |
| Non-cash lease expense | - | 0 |
| Deferred revenue | - | 0 |
| Accounts payable | 230,209 | 126,861 |
| Gain on exchange of warrants | - | 0 |
| Accrued expenses and other current liabilities | 126,545 | -263,560 |
| Net cash used in operating activities | -2,901,137 | -5,472,653 |
| Sale of marketable securities | 2,548,105 | 6,664,238 |
| Purchase of marketable securities | 550,467 | 2,128,680 |
| Purchases of equipment | 0 | 36,400 |
| Net cash provided by (used in) investing activities | 1,997,638 | 4,499,158 |
| Proceeds from issuance of common stock in at-the-market offering | 0 | 2,011,250 |
| Payment of issuance costs | 0 | 72,805 |
| Proceeds from exchange and issuance of warrants, net | - | 0 |
| Exercise of stock options | 0 | 42,411 |
| Deferred offering costs | 49,308 | 0 |
| Net cash provided by financing activities | -49,308 | 1,980,856 |
| Net increase in cash and cash equivalents | -952,807 | 1,007,361 |
| Cash and cash equivalents at beginning of period | 547,890 | - |
| Cash and cash equivalents at end of period | 602,444 | - |
BioRestorative Therapies, Inc. (BRTX)
BioRestorative Therapies, Inc. (BRTX)